People
The lung model in Draper’s new organ-on-a-chip platform, PREDICT96, replicates the structure and function of human lung tissue from donors with multiple patient profiles on a 96-well plate, increasing assay throughput by 10-fold.
Despite the bleak challenges brought on by COVID-19, Bill Sibold, executive vice president of Sanofi Genzyme, is optimistic that some of the greatest discoveries in medicine and treating various diseases are within the grasp of the pharmaceutical industry.
Biopharma and life sciences companies bolster their executive teams and board with these Movers & Shakers.
The supply chain that exists for traditional pharmaceuticals is woefully insufficient for regenerative medicine, according to Robert Lechich, principal manufacturing and supply chain consultant for Global OT/IT – Quality Services.
According to a brief report by Reuters, the drug company plans to hold meetings with staff representatives tomorrow and Monday of next week to describe a restructuring plan, according to four sources familiar with the matter.
The Brisbane, California-based company announced its plans to separate the two units and treat them as individual operations with individual managers.
COVID-19-related testimonies will continue in Congress today, with representatives from the Biotechnology Innovation Organization (BIO) expected to address the current pandemic as well as key priorities that will need to be in place in order to effectively respond to the next global viral threat.
Speaking before Congress on Tuesday, Dr. Anthony Fauci urged people to adopt strategies that involve wearing a mask in public, maintaining social distance and avoiding large gatherings of people.
Artificial intelligence (AI) is amplifying the pace of drug development, allowing developers to attack otherwise intractable problems and achieve results in weeks. Previously, results may have been impossible within any time frame.
With phase III trials underway and Fast Track designation from the FDA, “It’s, conservatively, at least one year ahead of everyone else’s,” John Temperato, president and CEO, told BioSpace.
PRESS RELEASES